Lonza Benelux

Foundation date

1897

Sector

#Biotechnology / R&D Services

Subsector

Lonza is one of the world’s largest companies for contract development and manufacturing, recognized for reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and over 35 years of experience in mammalian cell culture.

Lonza customers need to maintain high productivity, product quality and reproducibility when moving from the research phase into clinical and commercial manufacturing, rapidly bringing candidates to the clinic and products to market. A successful outcome will often require significant technical expertise and advanced development and manufacturing technologies.

In Lonza’s extensive contract development and manufacturing services portfolio, Lonza uses advanced technologies to quickly and efficiently deliver products such as monoclonal antibodies, complex proteins and recombinant proteins. Their biologics offering spans from preclinical services, clinical drug product and drug substance and commercial supply in Mammalian, Microbial, ADCs / Bioconjugates, mRNA and Cell & Gene Therapies.

Lonza works in partnership with customers of all sizes, from start-ups to large biotechs and pharmaceutical companies, and can tailor our products and services to your specific needs, budget and timelines

Upcoming events

Latest news

  • Scientists discover viral trapdoor blocking HIV and herpes

    1 day ago

  • UZ Leuven and KU Leuven invest 14 million euro in new cell and gene therapy facility

    Tuesday October 8th 2024

  • Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

    Monday October 7th 2024